

# Leo Kager

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9553176/publications.pdf>

Version: 2024-02-01

70  
papers

4,037  
citations

201385

27  
h-index

118652

62  
g-index

85  
all docs

85  
docs citations

85  
times ranked

4897  
citing authors

#	ARTICLE	IF	CITATIONS
1	Secondary malignant neoplasms after bone and soft tissue sarcomas in children, adolescents, and young adults. <i>Cancer</i> , 2022, 128, 1787-1800.	2.0	8
2	Clear cell sarcoma of the kidney in Austrian children: Long-term survival after relapse. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28860.	0.8	7
3	Occurrence of autoimmune pancreatitis after chronic immune thrombocytopenia in a Caucasian adolescent. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 918-922.	0.4	1
4	Extrasosseous osteoblastoma: A rare cause of breast mass in a prepubertal girl. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04094.	0.2	0
5	Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study. <i>European Journal of Cancer</i> , 2021, 151, 150-158.	1.3	19
6	Systematic review of the immunological landscape of Wilms tumors. <i>Molecular Therapy - Oncolytics</i> , 2021, 22, 454-467.	2.0	25
7	Osteosarcoma-Approach to Therapy. <i>Pediatric Oncology</i> , 2021, , 91-109.	0.5	10
8	Characteristics of Nephroblastoma/Nephroblastomatosis in Children with a Clinically Reported Underlying Malformation or Cancer Predisposition Syndrome. <i>Cancers</i> , 2021, 13, 5016.	1.7	6
9	Current Insights into the Management of Late Chemotherapy Toxicities in Pediatric Osteosarcoma Patients. <i>Cancer Management and Research</i> , 2021, Volume 13, 8989-8998.	0.9	7
10	Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093789.	1.4	8
11	Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency. <i>Blood</i> , 2020, 136, 2638-2655.	0.6	64
12	Pathological Fracture and Prognosis of High-Grade Osteosarcoma of the Extremities: An Analysis of 2,847 Consecutive Cooperative Osteosarcoma Study Group (COSS) Patients. <i>Journal of Clinical Oncology</i> , 2020, 38, 823-833.	0.8	45
13	Novel Compound Heterozygous Mutations in Two Families With Bernard-Soulier Syndrome. <i>Frontiers in Pediatrics</i> , 2020, 8, 589812.	0.9	4
14	Local Stage Dependent Necessity of Radiation Therapy in Rhabdoid Tumors of the Kidney (RTK). <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 667-675.	0.4	6
15	Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. <i>European Journal of Cancer</i> , 2019, 109, 36-50.	1.3	354
16	Polymerase Î deficiency causes syndromic immunodeficiency with replicative stress. <i>Journal of Clinical Investigation</i> , 2019, 129, 4194-4206.	3.9	41
17	Novel guidelines on surveillance for breast cancer, cardiomyopathy, male gonadotoxicity, and premature ovarian insufficiency from the PanCare and International Guideline Harmonization Group on long-term follow-up after cancer in childhood. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 54-58.	0.3	1
18	High-dose treatment for malignant rhabdoid tumor of the kidney: No evidence for improved survival - The Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) experience. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26746.	0.8	35

#	ARTICLE	IF	CITATIONS
19	Thoracic Actinomyces With Infiltration of the Spine: An Oncological Pitfall. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, 468-471.	0.3	5
20	Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literatureâ€”A report from the SIOP Renal Tumor Study Group. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26849.	0.8	11
21	Pharmacogenomics and Hematologic Diseases. , 2018, , 79-91.		0
22	Outcome of two patients with bilateral nephroblastomatosis/Wilms tumour treated with an add-on 13-cis retinoic acid therapy â€” Case report. <i>Pediatric Hematology and Oncology</i> , 2018, 35, 218-224.	0.3	11
23	Targeted mutation screening of 292 candidate genes in 38 children with inborn haematological cytopenias efficiently identifies novel diseaseâ€”causing mutations. <i>British Journal of Haematology</i> , 2018, 182, 251-258.	1.2	12
24	High-Grade Osteosarcoma of the Foot: Presentation, Treatment, Prognostic Factors, and Outcome of 23 Cooperative Osteosarcoma Study Group COSS Patients. <i>Sarcoma</i> , 2018, 2018, 1-11.	0.7	9
25	Osteosarkome. , 2018, , 509-525.		0
26	Reduced-intensity conditioning and stem cell transplantation in infants with Diamond Blackfan anemia. <i>Haematologica</i> , 2017, 102, e73-e75.	1.7	12
27	Denosumab treatment for progressive skull base giant cell tumor of bone in a 14-year old female â€” a case report and literature review. <i>Italian Journal of Pediatrics</i> , 2017, 43, 32.	1.0	16
28	Band 3 null<sup>VIENNA</sup>, a novel homozygous <i>SLC4A1</i> p.Ser477X variant causing severe hemolytic anemia, dyserythropoiesis and complete distal renal tubular acidosis. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26227.	0.8	19
29	Novel insights and therapeutic interventions for pediatric osteosarcoma. <i>Future Oncology</i> , 2017, 13, 357-368.	1.1	178
30	Advances in the management of osteosarcoma. <i>F1000Research</i> , 2016, 5, 2767.	0.8	105
31	Two Novel Missense Mutations and a 5bp Deletion in the Erythroid-Specific Promoter of the <i>PKLR</i> Gene in Two Unrelated Patients With Pyruvate Kinase Deficient Transfusion-Dependent Chronic Nonspherocytic Hemolytic Anemia. <i>Pediatric Blood and Cancer</i> , 2016, 63, 914-916.	0.8	6
32	Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 1396-1408.	5.1	356
33	Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3195-3203.	0.8	105
34	NF-Î²B1 Haploinsufficiency Causing Immunodeficiency and EBV-Driven Lymphoproliferation. <i>Journal of Clinical Immunology</i> , 2016, 36, 533-540.	2.0	113
35	The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24â€”25, 2015. Workshop Report. <i>Clinical Sarcoma Research</i> , 2016, 6, 3.	2.3	14
36	Multiple relapses in high-grade osteosarcoma: When to stop aggressive therapy?. <i>Pediatric Blood and Cancer</i> , 2015, 62, 529-530.	0.8	6

#	ARTICLE	IF	CITATIONS
37	Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2279-2287.	0.8	329
38	Can pharmacogenomics help to improve therapy in patients with high-grade osteosarcoma?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1025-1028.	1.5	9
39	Absence of Band 3 in Severe Dyserythropoietic/Hemolytic Anemia with Complete Distal Renal Acidosis and a Novel Homozygous Exon 12 C.1430C>a (p.Ser477X) SLC4A1 Gene Mutation. <i>Blood</i> , 2015, 126, 945-945.	0.6	1
40	Event-free survival and overall survival in 2,253 patients with osteosarcoma registered to EURAMOS-1.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10512-10512.	0.8	4
41	Direct and Indirect Targets of the E2A-PBX1 Leukemia-Specific Fusion Protein. <i>PLoS ONE</i> , 2014, 9, e87602.	1.1	34
42	Malignant rhabdoid tumor of the kidney: significantly improved response to pre-operative treatment intensified with doxorubicin. <i>Cancer Genetics</i> , 2014, 207, 434-436.	0.2	14
43	Long-term survival of patients suffering from solid extra-cranial neoplasias after dendritic cell-based cancer immune therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3096-3096.	0.8	5
44	Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 2303-2312.	0.8	161
45	MAP plus maintenance pegylated interferon Î±-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 "good response" randomization.. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA10504-LBA10504.	0.8	14
46	MAP plus maintenance pegylated interferon Î±-2b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomization.. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA10504-LBA10504.	0.8	4
47	Thiamine-responsive megaloblastic anemia (TRMA) in an Austrian boy with compound heterozygous SLC19A2 mutations. <i>European Journal of Pediatrics</i> , 2012, 171, 1711-1715.	1.3	24
48	Results of children with renal tumors treated in the Austrian "Hungarian Wilms Tumor Study 1989 and the International Society of Pediatric Oncology (SIOP) 93-01/GPOH trial in Austria. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 289-295.	0.3	2
49	EURAMOS-1 study: Recruitment, characteristics, and initial treatment of more than 2,000 patients (pts) with high-grade osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10081-10081.	0.8	3
50	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 679-686.	0.7	120
51	Osteosarcoma in very young children. <i>Cancer</i> , 2010, 116, 5316-5324.	2.0	54
52	Old drug "New insights" Better treatment?. <i>Leukemia Research</i> , 2010, 34, 1558-1559.	0.4	0
53	Review of mifamurtide in the treatment of patients with osteosarcoma. <i>Therapeutics and Clinical Risk Management</i> , 2010, 6, 279.	0.9	86
54	Synchronous and Metachronous Lung Metastases in High-grade Osteosarcoma. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 94-95.	0.6	4

#	ARTICLE	IF	CITATIONS
55	Pharmacogenomics to improve childhood acute lymphoblastic leukaemia therapy. <i>Memo - Magazine of European Medical Oncology</i> , 2009, 2, 65-70.	0.3	2
56	Pharmacogenetics in Acute Lymphoblastic Leukemia. <i>Seminars in Hematology</i> , 2009, 46, 39-51.	1.8	55
57	High-dose Methotrexate: The Rationale. <i>Journal of Pediatric Hematology/Oncology</i> , 2009, 31, 224-225.	0.3	3
58	Antileukemic drug effects in childhood acute lymphoblastic leukemia. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 401-413.	1.3	1
59	In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression Profile. <i>PLoS Medicine</i> , 2008, 5, e83.	3.9	75
60	Cutting Edge: A Hypomorphic Mutation in $Ig\lambda^2$ (CD79b) in a Patient with Immunodeficiency and a Leaky Defect in B Cell Development. <i>Journal of Immunology</i> , 2007, 179, 2055-2059.	0.4	74
61	Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children. <i>Haematologica</i> , 2007, 92, 1561-1564.	1.7	55
62	Pharmacogenomics of acute lymphoblastic leukemia. <i>Current Opinion in Hematology</i> , 2006, 13, 260-265.	1.2	38
63	Skip Metastases in Osteosarcoma: Experience of the Cooperative Osteosarcoma Study Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 1535-1541.	0.8	122
64	Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. <i>Journal of Clinical Investigation</i> , 2005, 115, 110-117.	3.9	129
65	Treatment Response and Outcome in Childhood $t(1;19)$ /TCF3-PBX1 Positive Acute Lymphoblastic Leukemia: A Report from the Austrian BFM Group. <i>Blood</i> , 2005, 106, 1458-1458.	0.6	1
66	A substrate specific functional polymorphism of human $\hat{I}^3$ -glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 557-567.	5.7	83
67	Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis. <i>Blood</i> , 2004, 104, 1435-1441.	0.6	38
68	Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols. <i>Journal of Clinical Oncology</i> , 2003, 21, 2011-2018.	0.8	765
69	Chromosomal regions involved in the pathogenesis of osteosarcomas. <i>Genes Chromosomes and Cancer</i> , 2000, 28, 329-336.	1.5	101
70	Case Report: Refractory Cytopenia With a Switch From a Transient Monosomy 7 to a Disease-Ameliorating $del(20q)$ in a NHEJ1-Deficient Long-term Survivor. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1